drug_name event_name drug_id event_id drug_and_event_name
5 Ciprofloxacin Infection AND/OR inflammatory reaction due to internal prosthetic device, implant AND/OR graft 1797513 440276 Ciprofloxacin & Infection AND/OR inflammatory reaction due to internal prosthetic device, implant AND/OR graft 
## Chronograph ##

## Basic demographic table##
1: DEC cohort n Percentage 2: Drug cohort n Percentage 3: Event cohort n Percentage 4: All drugs cohort n Percentage
Total 26 100 Total 1000 100 Total 185 100 Total 1000 100
Sex gender = FEMALE 18 69 Sex gender = FEMALE 619 62 Sex gender = FEMALE 104 56 Sex gender = FEMALE 546 55
gender = MALE 8 31 gender = MALE 381 38 gender = MALE 81 44 gender = MALE 454 45
Age (0,20] 0 0 Age (0,20] 0 0 Age (0,20] 0 0 Age (0,20] 0 0
(20,30] 0 0 (20,30] 3 0 (20,30] 1 1 (20,30] 8 1
(30,40] 0 0 (30,40] 24 2 (30,40] 5 3 (30,40] 13 1
(40,50] 1 4 (40,50] 55 6 (40,50] 7 4 (40,50] 44 4
(50,60] 1 4 (50,60] 73 7 (50,60] 13 7 (50,60] 55 6
(60,70] 6 23 (60,70] 209 21 (60,70] 35 19 (60,70] 224 22
(70,80] 13 50 (70,80] 334 33 (70,80] 62 34 (70,80] 386 39
(80,90] 3 12 (80,90] 229 23 (80,90] 50 27 (80,90] 225 22
(90,110] 2 8 (90,110] 73 7 (90,110] 12 6 (90,110] 45 4
Median 73 IQR=(67, 80) Median 74 IQR=(67, 83) Median 75 IQR=(68, 83) Median 74 IQR=(68, 81) 
## Gender distribution ##
## DEC vs. drug ##
Characteristic % (n = 26) % (n = 1,000) Std.Diff Characteristic % (n = 26) % (n = 1,000) Std.Diff
Age group Viral hepatitis C 7.7 1.4 -0.31
25 - 29 0 0.3 0.08 Visual system disorder 38.5 33.9 -0.10
30 - 34 0 0.7 0.12 Medical history: Cardiovascular disease
35 - 39 0 1.0 0.14 Atrial fibrillation 46.2 29.0 -0.36
40 - 44 3.8 2.1 -0.10 Cerebrovascular disease 11.5 8.6 -0.10
45 - 49 0 3.3 0.26 Coronary arteriosclerosis 61.5 29.1 -0.69
50 - 54 0 2.4 0.22 Heart disease 96.2 58.0 -1.02
55 - 59 3.8 5.1 0.06 Heart failure 53.8 25.6 -0.60
60 - 64 0 4.3 0.30 Ischemic heart disease 26.9 16.2 -0.26
65 - 69 23.1 14.9 -0.21 Peripheral vascular disease 57.7 30.0 -0.58
70 - 74 26.9 17.2 -0.24 Pulmonary embolism 3.8 3.2 -0.04
75 - 79 11.5 15.0 0.10 Venous thrombosis 15.4 8.6 -0.21
80 - 84 19.2 13.5 -0.16 Medical history: Neoplasms
85 - 89 3.8 11.1 0.28 Hematologic neoplasm 23.1 8.2 -0.42
90 - 94 7.7 5.4 -0.09 Malignant lymphoma 11.5 3.5 -0.31
95 - 99 0 2.9 0.24 Malignant neoplasm of anorectum 0 1.3 0.16
100 - 104 0 0.8 0.13 Malignant neoplastic disease 50.0 26.2 -0.51
Gender: female 69.2 61.9 -0.15 Malignant tumor of breast 3.8 3.8 0.00
Medical history: General Malignant tumor of colon 7.7 4.0 -0.16
Acute respiratory disease 50.0 23.8 -0.56 Malignant tumor of lung 15.4 2.5 -0.46
Attention deficit hyperactivity disorder 0 0.1 0.04 Malignant tumor of urinary bladder 3.8 2.5 -0.08
Chronic liver disease 15.4 3.3 -0.42 Medication use
Chronic obstructive lung disease 30.8 11.3 -0.49 Agents acting on the renin-angiotensin system 73.1 68.0 -0.11
Crohn’s disease 3.8 1.2 -0.17 Antibacterials for systemic use 65.4 48.4 -0.35
Dementia 7.7 13.1 0.18 Antidepressants 73.1 57.5 -0.33
Depressive disorder 7.7 10.9 0.11 Antiepileptics 30.8 34.1 0.07
Diabetes mellitus 84.6 50.6 -0.78 Antiinflammatory and antirheumatic products 42.3 36.4 -0.12
Gastroesophageal reflux disease 7.7 13.9 0.20 Antineoplastic agents 11.5 12.1 0.02
Gastrointestinal hemorrhage 19.2 6.3 -0.39 Antipsoriatics 0 0.4 0.09
Human immunodeficiency virus infection 0 0.7 0.12 Antithrombotic agents 57.7 51.2 -0.13
Hyperlipidemia 38.5 25.4 -0.28 Beta blocking agents 73.1 63.4 -0.21
Hypertensive disorder 11.5 5.0 -0.24 Calcium channel blockers 73.1 53.2 -0.42
Lesion of liver 19.2 3.7 -0.50 Diuretics 57.7 66.0 0.17
Obesity 3.8 7.0 0.14 Drugs for acid related disorders 42.3 48.4 0.12
Osteoarthritis 53.8 37.1 -0.34 Drugs for obstructive airway diseases 34.6 37.8 0.07
Pneumonia 11.5 7.1 -0.15 Drugs used in diabetes 46.2 53.7 0.15
Psoriasis 0 1.8 0.19 Immunosuppressants 7.7 5.0 -0.11
Renal impairment 73.1 26.2 -1.06 Lipid modifying agents 84.6 71.3 -0.33
Rheumatoid arthritis 7.7 6.2 -0.06 Opioids 42.3 31.4 -0.23
Schizophrenia 23.1 6.8 -0.47 Psycholeptics 57.7 52.8 -0.10
Ulcerative colitis 0 0.2 0.06 Psychostimulants, agents used for adhd and nootropics 11.5 14.3 0.08
Urinary tract infectious disease 53.8 21.4 -0.71 
## Event vs. All ##
Characteristic % (n = 185) % (n = 1,000) Std.Diff Characteristic % (n = 185) % (n = 1,000) Std.Diff
Age group Urinary tract infectious disease 34.6 19.1 -0.36
25 - 29 0.5 0.6 0.01 Viral hepatitis C 4.3 1.5 -0.17
30 - 34 1.6 1.0 -0.05 Visual system disorder 49.2 40.1 -0.18
35 - 39 1.1 0.2 -0.11 Medical history: Cardiovascular disease
40 - 44 2.2 0.9 -0.10 Atrial fibrillation 49.7 26.2 -0.50
45 - 49 1.6 3.0 0.09 Cerebrovascular disease 20.0 8.2 -0.34
50 - 54 2.2 2.8 0.04 Coronary arteriosclerosis 51.4 29.0 -0.47
55 - 59 4.3 2.9 -0.08 Heart disease 86.5 57.6 -0.68
60 - 64 1.6 2.9 0.09 Heart failure 52.4 22.6 -0.65
65 - 69 14.6 16.1 0.04 Ischemic heart disease 25.9 12.6 -0.34
70 - 74 17.8 22.7 0.12 Peripheral vascular disease 44.3 27.1 -0.37
75 - 79 15.7 17.1 0.04 Pulmonary embolism 6.5 2.6 -0.19
80 - 84 17.3 13.9 -0.09 Venous thrombosis 16.8 8.1 -0.26
85 - 89 10.3 10.0 -0.01 Medical history: Neoplasms
90 - 94 4.9 3.7 -0.06 Hematologic neoplasm 24.3 6.5 -0.51
95 - 99 2.7 1.9 -0.05 Malignant lymphoma 10.3 4.0 -0.25
100 - 104 1.6 0.3 -0.14 Malignant neoplasm of anorectum 3.2 1.7 -0.10
Gender: female 56.2 54.6 -0.03 Malignant neoplastic disease 54.1 26.6 -0.58
Medical history: General Malignant tumor of breast 7.0 3.6 -0.15
Acute respiratory disease 35.7 21.5 -0.32 Malignant tumor of colon 8.1 4.1 -0.17
Attention deficit hyperactivity disorder 0 0.2 0.06 Malignant tumor of lung 4.9 4.1 -0.04
Chronic liver disease 7.0 2.6 -0.21 Malignant tumor of urinary bladder 6.5 2.6 -0.19
Chronic obstructive lung disease 21.1 8.9 -0.35 Medication use
Crohn’s disease 1.1 1.0 -0.01 Agents acting on the renin-angiotensin system 42.7 0 -1.22
Dementia 22.7 10.7 -0.33 Antibacterials for systemic use 38.4 0 -1.12
Depressive disorder 14.1 7.6 -0.21 Antidepressants 38.4 0 -1.12
Diabetes mellitus 73.0 50.5 -0.48 Antiepileptics 23.8 0 -0.79
Gastroesophageal reflux disease 26.5 13.7 -0.32 Antiinflammatory and antirheumatic products 23.8 0 -0.79
Gastrointestinal hemorrhage 8.1 4.9 -0.13 Antineoplastic agents 11.4 0 -0.51
Human immunodeficiency virus infection 1.6 0.5 -0.11 Antithrombotic agents 38.4 0 -1.12
Hyperlipidemia 34.1 24.3 -0.22 Beta blocking agents 34.6 0 -1.03
Hypertensive disorder 4.3 5.3 0.05 Calcium channel blockers 30.3 0 -0.93
Lesion of liver 5.9 3.4 -0.12 Diuretics 40.0 0 -1.15
Obesity 11.9 5.9 -0.21 Drugs for acid related disorders 30.8 0 -0.94
Osteoarthritis 61.1 38.1 -0.47 Drugs for obstructive airway diseases 22.7 0 -0.77
Pneumonia 12.4 5.4 -0.25 Drugs used in diabetes 35.1 0 -1.04
Psoriasis 2.2 1.7 -0.03 Immunosuppressants 3.8 0 -0.28
Renal impairment 41.6 22.5 -0.42 Lipid modifying agents 43.8 0 -1.25
Rheumatoid arthritis 8.6 6.0 -0.10 Opioids 33.5 0 -1.00
Schizophrenia 8.1 4.0 -0.17 Psycholeptics 42.7 0 -1.22
Ulcerative colitis 1.1 0.3 -0.09 Psychostimulants, agents used for adhd and nootropics 9.7 0 -0.46 
## Drug vs. All ##
Characteristic % (n = 185) % (n = 1,000) Std.Diff Characteristic % (n = 185) % (n = 1,000) Std.Diff
Age group Urinary tract infectious disease 34.6 19.1 -0.36
25 - 29 0.5 0.6 0.01 Viral hepatitis C 4.3 1.5 -0.17
30 - 34 1.6 1.0 -0.05 Visual system disorder 49.2 40.1 -0.18
35 - 39 1.1 0.2 -0.11 Medical history: Cardiovascular disease
40 - 44 2.2 0.9 -0.10 Atrial fibrillation 49.7 26.2 -0.50
45 - 49 1.6 3.0 0.09 Cerebrovascular disease 20.0 8.2 -0.34
50 - 54 2.2 2.8 0.04 Coronary arteriosclerosis 51.4 29.0 -0.47
55 - 59 4.3 2.9 -0.08 Heart disease 86.5 57.6 -0.68
60 - 64 1.6 2.9 0.09 Heart failure 52.4 22.6 -0.65
65 - 69 14.6 16.1 0.04 Ischemic heart disease 25.9 12.6 -0.34
70 - 74 17.8 22.7 0.12 Peripheral vascular disease 44.3 27.1 -0.37
75 - 79 15.7 17.1 0.04 Pulmonary embolism 6.5 2.6 -0.19
80 - 84 17.3 13.9 -0.09 Venous thrombosis 16.8 8.1 -0.26
85 - 89 10.3 10.0 -0.01 Medical history: Neoplasms
90 - 94 4.9 3.7 -0.06 Hematologic neoplasm 24.3 6.5 -0.51
95 - 99 2.7 1.9 -0.05 Malignant lymphoma 10.3 4.0 -0.25
100 - 104 1.6 0.3 -0.14 Malignant neoplasm of anorectum 3.2 1.7 -0.10
Gender: female 56.2 54.6 -0.03 Malignant neoplastic disease 54.1 26.6 -0.58
Medical history: General Malignant tumor of breast 7.0 3.6 -0.15
Acute respiratory disease 35.7 21.5 -0.32 Malignant tumor of colon 8.1 4.1 -0.17
Attention deficit hyperactivity disorder 0 0.2 0.06 Malignant tumor of lung 4.9 4.1 -0.04
Chronic liver disease 7.0 2.6 -0.21 Malignant tumor of urinary bladder 6.5 2.6 -0.19
Chronic obstructive lung disease 21.1 8.9 -0.35 Medication use
Crohn’s disease 1.1 1.0 -0.01 Agents acting on the renin-angiotensin system 42.7 0 -1.22
Dementia 22.7 10.7 -0.33 Antibacterials for systemic use 38.4 0 -1.12
Depressive disorder 14.1 7.6 -0.21 Antidepressants 38.4 0 -1.12
Diabetes mellitus 73.0 50.5 -0.48 Antiepileptics 23.8 0 -0.79
Gastroesophageal reflux disease 26.5 13.7 -0.32 Antiinflammatory and antirheumatic products 23.8 0 -0.79
Gastrointestinal hemorrhage 8.1 4.9 -0.13 Antineoplastic agents 11.4 0 -0.51
Human immunodeficiency virus infection 1.6 0.5 -0.11 Antithrombotic agents 38.4 0 -1.12
Hyperlipidemia 34.1 24.3 -0.22 Beta blocking agents 34.6 0 -1.03
Hypertensive disorder 4.3 5.3 0.05 Calcium channel blockers 30.3 0 -0.93
Lesion of liver 5.9 3.4 -0.12 Diuretics 40.0 0 -1.15
Obesity 11.9 5.9 -0.21 Drugs for acid related disorders 30.8 0 -0.94
Osteoarthritis 61.1 38.1 -0.47 Drugs for obstructive airway diseases 22.7 0 -0.77
Pneumonia 12.4 5.4 -0.25 Drugs used in diabetes 35.1 0 -1.04
Psoriasis 2.2 1.7 -0.03 Immunosuppressants 3.8 0 -0.28
Renal impairment 41.6 22.5 -0.42 Lipid modifying agents 43.8 0 -1.25
Rheumatoid arthritis 8.6 6.0 -0.10 Opioids 33.5 0 -1.00
Schizophrenia 8.1 4.0 -0.17 Psycholeptics 42.7 0 -1.22
Ulcerative colitis 1.1 0.3 -0.09 Psychostimulants, agents used for adhd and nootropics 9.7 0 -0.46 
## Top drugs and conditions for DEC ##
drugs_180_days n_180_days
beta blocking agents 38
antithrombotic agents 30
all other therapeutic products 26
cardiovascular system 26
alimentary tract and metabolism 25
nervous system 25
antihistamines for systemic use 24
respiratory system 24
lipid modifying agents 22
lipid modifying agents, plain 22
stomatological preparations 22
systemic hormonal preparations, excl. sex hormones and insulins 21
hmg coa reductase inhibitors 20
agents acting on the renin-angiotensin system 19
antidepressants 19
antiinfectives for systemic use 19
calcium channel blockers 19
psychoanaleptics 19
analgesics 18
blood and blood forming organs 18
antibacterials for systemic use 17
dermatologicals 17
musculo-skeletal system 17
non-selective monoamine reuptake inhibitors 17
antiepileptics 16
cond_180_days n_180_days
heart disease 25
pain 25
pain finding at anatomical site 25
vascular disorder 25
kidney disease 23
arthropathy 22
diabetes mellitus 22
inflammation of specific body organs 22
inflammation of specific body systems 22
measurement finding outside reference range 22
soft tissue lesion 22
pain of truncal structure 21
abnormal blood cell count 20
type 2 diabetes mellitus 20
anemia 19
cytopenia 19
erythropenia 19
hemoglobin level outside reference range 19
hemoglobin low 19
measurement finding below reference range 19
rbc count abnormal 19
rbc count low 19
renal impairment 19
structural disorder of heart 19
arteriosclerotic vascular disease 17